Crossmark

Impact of treatment strategies incorporating sacubitril/valsartan on achievement of guideline-recommended blood pressure targets and representative safety outcomes

Crossref DOI link: https://doi.org/10.1038/s41440-025-02537-w

Published Online: 2026-01-14

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Katsuya, Tomohiro

Nakatsu, Fumiko

Eguchi, Shunsuke

Nakamura, Yumiko

Matsukawa, Miyuki

Iekushi, Kazuma

Hiramitsu, Shinya
License Information

Text and Data Mining valid from 2026-01-14

Version of Record valid from 2026-01-14
More Information

Article History

Received: 17 July 2025

Revised: 8 December 2025

Accepted: 17 December 2025

First Online: 14 January 2026

Compliance with ethical standards

:

: Honoraria and fees for promotional material: TK (Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., CureApp, Inc.), SH (Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Bayer Yakuhin, Ltd.); Employment: FN, SE, KI, SH’s family member (Novartis Pharma K.K.), YN, MM (Otsuka Pharmaceutical Co., Ltd.).

Document is current

Any future updates will be listed below